Causes of renal allograft loss in black vs. White transplant recipients in the cyclosporine era

Clinical Transplantation

Volumn 11, Issue 3, 1997, Pages 231-236

  Valente, John F ^a   Hariharan, Sundaram ^a   Peddi, V Ram ^a   Schroeder, Timothy J ^a   Ogle, Cora K ^a   Alexander, J Wesley ^a   First, M Roy ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

Cyclosporine; Kidney; Race; Rejection; Transplantation

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE; ARTICLE; CADAVER KIDNEY; CAUCASIAN; FEMALE; GENDER; HLA MATCHING; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; MALE; NEGRO; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RACE DIFFERENCE; REOPERATION;

ACUTE DISEASE; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; ANALYSIS OF VARIANCE; CHRONIC DISEASE; CYCLOSPORINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; OHIO; REOPERATION; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE; TISSUE AND ORGAN PROCUREMENT; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030969169     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. TERASAKI PI, MICJEY MR, CECKA JM, et al. Overview. In: TERASAKI PI, ed. Clinical Transplants 1987. Los Angeles: UCLA Tissue Typing Laboratory 1988: 467.
2. OPELZ G, MICKEY MR, TERASAKI PI. Influence of race on kidney transplant survival. Transpl Proc 1977: 9: 137.
3. SCHROEDER TJ, HARIHARAN S, FIRST MR. Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations. Transpl Proc 1995: 27: 837.
4. OJD AO, PORT FK, MAUGER EA, WOLFE RA, LEICHTMAN AB. Relative impact of donor type on renal allograft survival in black and white recipients. Am J Kidney Dis 1995: 25: 623.
5. OPELZ G, SCHWARTZ V, ENGELMANN D, et al. Long-term impact of HLA matching on kidney graft survival in cyclosporine-treated recipients. Transpl Proc 1991: 23: 373.
6. KALIL RSN, HEIM-DUTHOY KL, KAISISKE BL. Patients with a low income have reduced renal allograft survival. Am J Kidney Dis 1992: 20: 63.
7. KILEY DJ, LAM CS, POLLAK R. A study of treatment compliance following kidney transplantation. Transplantation 1993: 55: 51.
8. ROVELLI M, PALMERI D, VOSSLER E, BARTUS S, HULL D, SCHWEIZER R. Noncompliance in organ transplant recipients. Transpl Proc 1989: 21: 833.
9. DUNN J, VATHSALA A, GOLDEN D, et al. Impact of race on the outcome of renal transplantation under cyclosporinprednisone. Transpl Proc 1989: 21: 3946.
10. COSIO FG, DILLON JJ, FALKENHAIN ME, et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int 1995: 47: 1136.
11. KASSISKE BL. NEYLAN JF, RIGGIO RR, et al. The Effect of race on access and outcome in transplantation. N Engl J Med 1991: 324: 302.
12. DAWIDSON IJA, COORPENDER L, FISHER D, et al. Impact of race on renal transplant outcome. Transplantation 1990: 49: 63.
13. BUTKUS DE, KIRCHNER KA, KRUEGER R, CRUSE J, RAJU S. Racial differences in primary renal cadaveric allograft survival. Clin Transpl 1991: 5: 411.
14. HARIHARAN S, SCHROEDER TJ, FIRST MR. Effect of race on renal transplant outcome. Clin Transpl 1993: 7: 235.
15. BUTKUS DE, MEYDRECH EF, RAJU SS. Racial differences in the survival of cadaveric renal allografts. N Engl J Med 1992: 327: 840.
16. DAVIES CB, ALEXANDER JW, COFER BR, FIRST MR, SCHROEDER TJ. Efficacy of a single pretransplant donor specific transfusion and cyclosporine A administered 24-48 hours prior to one-haplotype mismatched living related donor kidney transplant. Ann Surg 1992: 215: 618.
17. SCHROEDER TJ, FIRST MR, MANSOUR ME, ALEXANDER JW, PENN I. Prophylactic use of OKT3 in immunological high risk renal transplant recipients. Am J Kidney Dis 1898: 14 Suppl 2: 14.
18. FISCHER RA, TCHERVENKOV JI, SCHROEDER TJ, et al. Efficacy of Induction therapy in cadaveric renal transplantation comparing rabbit antithymocyte serum and Minnesota anti-lymphoblast globulin. Transpl Proc 1991: 23: 1253.
19. SOLEZ K, AXELSEN RA, BENEDIKTSSON H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993: 44: 411.
20. SCHROEDER TJ, WEISS MA, SMITH RD, STEPHENS GW, FIRST MR. The efficacy of OKT3 in vascular rejection. Transplantation 1991: 51: 312.
21. CECKA JM, TERASAKI PI. The UNOS scientific renal transplant registry. In: Terasaki PI, Cecka JM, eds. Clinical Transplants 1993. Los Angeles: UCLA Tissue Typing Laboratory 1994: 1.
22. TAKEMOTO S, TERASAKI PI. A comparison of kidney transplant survival in white and black recipients. Transplant Proc 1989: 21: 3865.
23. LAZDA VA. The impact of HLA frequency differences in races on the access to optimally HLA-matched cadaver renal transplants. Transplantation 1992: 53: 352.
24. BARGER B, SHROYER TW, HUDSON SI, et al. The impact of the UNOS mandatory sharing policy on recipients of the black and white races - experience at single renal transplant center. Transplantation 1992: 53: 770.
25. KERMAN RH, KIMBALL PH, VAN BUREN CT, et al. Influence of race on crossmatch outcome and recipient eligibility for transplantation. Transplantation 1992: 53: 64.
26. LAZDA VA, GADDIS PJ, STORMOEN BM, FABREGA AJ, POLLAK R. Presensitization and frequency of positive crossmatches in black and nonblack renal transplant candidates. Transpl Proc 1993: 25: 2411.
27. WELLER JM, WU SC, FERGUSON CW, PORT FK. Influence of race of cadaveric kidney donor and recipient on graft survival: a multifactorial analysis. Am J Kidney Dis 1987: 9: 191.
28. ROSS W, SOLOMON H, REESE J, et al. Beneficial effects of HLA-DR3 gene expression on renal allograft survival in black recipients. Transpl Proc 1993: 25: 2408.
29. MENDEZ R, MENDEZ RG, CICCIARELLI J, et al. Matching, race, donor age, and cold ischemia effects at a single renal transplant center. Transpl Proc 1991: 23: 376.
30. OPELZ G, PFARR E, ENGELMANN A, KAPPEL E. Kidney graft survival rates in black cyclosporine-treated recipients. Transpl Proc 1989: 21: 3918.
31. KERMAN RH, KIMBALL PM, VAN BUREN CT, LEWIS RM, KAHAN BD. Stronger immune responsiveness of blacks vs. whites may account for renal allograft survival differences. Transpl Proc 1991: 23: 380.
32. SCHROEDER TJ, SHAH M, HARIHARAN S, FIRST MR. The difficulty of maintaining therapeutic cyclosporine blood levels in black renal transplant recipients. Transplantation (in press).
33. NEYLAN JF, DEIERHOI MH, and the US Mycophenolate Mofetil Study Group. Dose dependent prevention of acute renal transplant rejection in African-Americans receiving mycophenolate mofetil (MMF). ASTP Annual Meeting 1995: abstract 182: p119.
34. TILNEY NL, CHANG A, MILFORD EL, et al. Ten-year experience with cyclosporine as primary immunosuppression in recipients of renal alografts. Ann Surg 1991: 214: 42.
35. CECKA JM. Outcome statistics of renal transplants with an emphasis on long-term survival. Clin Transpl 1994: 8: 324.